IntriCon (NASDAQ:IIN) Upgraded to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of IntriCon (NASDAQ:IIN) from a sell rating to a hold rating in a research note released on Saturday morning, Zacks.com reports.

According to Zacks, “IntriCon designs, develops, engineers and manufactures microminiaturized medical and electronic products. The Company supplies microminiaturized components, systems and molded plastic parts, primarily to the hearing instrument manufacturing industry, as well as the computer, government, electronics, telecommunications and medical equipment industries. The Company has facilities in the United States, Asia and Europe. “

Other equities research analysts also recently issued research reports about the company. Stifel Nicolaus set a $36.00 price objective on IntriCon and gave the company a buy rating in a report on Friday, July 19th. ValuEngine upgraded IntriCon from a hold rating to a buy rating in a research note on Thursday. Finally, B. Riley set a $36.00 price target on IntriCon and gave the company a buy rating in a research note on Friday, July 19th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $38.75.

Shares of NASDAQ IIN traded down $0.26 during trading hours on Friday, hitting $17.83. The company had a trading volume of 107,517 shares, compared to its average volume of 166,708. The stock has a market capitalization of $158.05 million, a PE ratio of 27.86, a P/E/G ratio of 7.80 and a beta of 0.68. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.13 and a quick ratio of 2.23. IntriCon has a 1-year low of $16.81 and a 1-year high of $76.80. The firm’s 50 day moving average price is $21.22.

A number of hedge funds have recently bought and sold shares of IIN. BlackRock Inc. increased its position in IntriCon by 3.4% during the 4th quarter. BlackRock Inc. now owns 509,049 shares of the technology company’s stock worth $13,428,000 after buying an additional 16,512 shares during the period. Bank of New York Mellon Corp increased its position in IntriCon by 21.5% during the 4th quarter. Bank of New York Mellon Corp now owns 26,139 shares of the technology company’s stock worth $690,000 after buying an additional 4,627 shares during the period. Northern Trust Corp increased its position in IntriCon by 1.3% during the 4th quarter. Northern Trust Corp now owns 107,608 shares of the technology company’s stock worth $2,839,000 after buying an additional 1,375 shares during the period. Dimensional Fund Advisors LP increased its position in IntriCon by 11.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 343,667 shares of the technology company’s stock worth $9,066,000 after buying an additional 34,031 shares during the period. Finally, Stifel Financial Corp increased its position in IntriCon by 79.8% during the 4th quarter. Stifel Financial Corp now owns 35,125 shares of the technology company’s stock worth $930,000 after buying an additional 15,589 shares during the period. Hedge funds and other institutional investors own 72.40% of the company’s stock.

IntriCon Company Profile

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company operates in two segments, Body Worn Devices and Hearing Health Direct-To-Consumer. It offers micro-miniature products, microelectronics; micro-mechanical assemblies; high-precision injection-molded plastic components; and assemblies and software solutions for medical biotelemetry devices, hearing healthcare, and professional audio communication devices markets.

Recommended Story: Trading Ex-Dividend

Get a free copy of the Zacks research report on IntriCon (IIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IntriCon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntriCon and related companies with MarketBeat.com's FREE daily email newsletter.